Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy

Table 1

Comparison of survival probability with various regimens for advanced melanoma after 12 months of treatment.

Treatment regimen	Survival probability (%)	Reference
Dacarbazine	12	[40]
Dabrafenib + trametinib	46	[41]
Ipilimumab	46	[42]
Nivolumab	72.9	[42]
Pembrolizumab	74.1	[42]
Vemurafenib+ cobimetinib	73	[43]